Facebook
Twitter
LinkedIn
Forward
Keeping Up with the Evolving Treatment Landscape for Advanced/Metastatic Gastric/GEJ Cancer: Modeling Center of Excellence Practices
November 4, 2024
Enloe Health
Survival rates for patients with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancers remain poor with recurrence rates as high as 60%. Many patients with recurrence fail to receive more than one line of therapy despite evidence that eligible patients who receive second-line therapy have improved survival. While progress has been made in treating advanced/metastatic disease using targeted immunotherapies, testing of molecular biomarkers such as PD-L1, MSI, and HER2 are essential to guide personalized treatment approaches. Novel targets and therapies are also anticipated for these patients. To support clinical teams with biomarker testing and optimal treatment selection practices, this series of complimentary, 1-hour programs, conveniently offered at the point-of-care, synergistically interweaves evidence-based knowledge with operational frameworks to support practices of all sizes with enhancing patient care.
Educational Partner: Academy for Continued Healthcare Learning (ACHL)
Commercial Support: Support for this activity has been provided through an educational grant from Merck & Co., Inc. and Astellas Pharmaceuticals.
Target Audience
This activity is intended for medical oncologists, surgical oncologists, advanced practice clinicians, oncology nurses, and other members of the multidisciplinary/multispecialty team who treat patients with gastric/GEJ cancer.
Learning Objectives
Upon completion of this activity, learners will be able to:
- Develop models for early and effective biomarker testing;
- Assess the most recent evidence with selecting and sequencing treatments;
- Create appropriate gastric/GEJ cancer treatment plans that implement the latest data and recommendations;
- Incorporate multidisciplinary strategies to manage potential gastric/GEJ cancer treatment-related adverse events.
You may also be interested in
Online Webinar
Monterey, CA
United States
WANT TO KNOW MORE?
Visit the Academy for Continued Healthcare Learning (ACHL) website! For additional questions, contact ACHL via their website.
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at https://www.achlcme.org.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
FACULTY
Manish A. Shah, MD, FASCO
Bartlett Family Professor of Gastrointestinal Oncology
Chief, Solid Tumor Oncology
Weill Cornell Medicine
New York, NY
Geoffrey Ku, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Bartlett Family Professor of Gastrointestinal Oncology
Chief, Solid Tumor Oncology
Weill Cornell Medicine
New York, NY
Geoffrey Ku, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University Of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
Registration: To view this activity, you will need to visit ACHL's website.
If you are logged in, click on the "Complete Activity" button below!
If you are logged in, click on the "Complete Activity" button below!
Please login or create an account to proceed.